Connor, Clark & Lunn Investment Management (CC&L)’s Apellis Pharmaceuticals APLS Stock Holding History

Connor, Clark & Lunn Investment Management (CC&L)’s Portfolio APLS Stock Details APLS Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2025 Q3	–	Sell	-118,724	Closed	-$2.06M	–	1493
2025 Q2	$2.06M	Sell	118,724 -13,171	-10%	-$244K	0.01%	854
2025 Q1	$2.88M	Buy	131,895 +118,417	+879%	+$3.27M	0.01%	634
2024 Q4	$430K	Buy	+13,478	New	+$405K	﹤0.01%	1180
2023 Q3	–	Sell	-149,976	Closed	-$13.7M	–	1353
2023 Q2	$13.7M	Sell	149,976 -2,019	-1%	-$174K	0.07%	208
2023 Q1	$10M	Buy	151,995 +75,114	+98%	+$4.33M	0.05%	253
2022 Q4	$3.98M	Buy	76,881 +71,567	+1,347%	+$3.8M	0.02%	394
2022 Q3	$363K	Buy	+5,314	New	+$314K	﹤0.01%	879
2022 Q1	–	Sell	-9,406	Closed	-$445K	–	1028
2021 Q4	$445K	Sell	9,406 -68,089	-88%	-$2.68M	﹤0.01%	822
2021 Q3	$2.55M	Buy	77,495 +59,074	+321%	+$3.32M	0.01%	473
2021 Q2	$1.16M	Buy	+18,421	New	+$951K	0.01%	647

Other funds holding APLS

ACA

Avoro Capital Advisors New York $10.2B AUM 149.19% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return

Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return

DTC

Deep Track Capital Greenwich, Connecticut $6.12B AUM 144% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

AQR Capital Management Greenwich, Connecticut $218B AUM 29.41% 1-Year Est. Return

Jennison Associates New York $167B AUM 44.17% 1-Year Est. Return

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

EcoR1 Capital San Francisco, California $2.36B AUM 204.53% 1-Year Est. Return

Connor, Clark & Lunn Investment Management (CC&L)'s APLS Position: Q3 2025 in Review

Connor, Clark & Lunn Investment Management (CC&L) sold out of Apellis Pharmaceuticals (APLS) in Q3 2025, closing a stake of 118,724 shares — an estimated $2.06M sold.

Connor, Clark & Lunn Investment Management (CC&L) first reported a position in APLS in Q2 2021 and held it in 10 quarters. The position peaked at $13.7M in Q2 2023. 273 funds tracked by Wall St. Rank hold APLS as of Q3 2025.

Connor, Clark & Lunn Investment Management (CC&L) reported no remaining Apellis Pharmaceuticals position as of Q3 2025 after selling out during the quarter.
Connor, Clark & Lunn Investment Management (CC&L) sold 118,724 Apellis Pharmaceuticals shares in Q3 2025, an estimated $2.06M.
Connor, Clark & Lunn Investment Management (CC&L) first reported a position in Apellis Pharmaceuticals in Q2 2021 and held it in 10 quarters.
Connor, Clark & Lunn Investment Management (CC&L)'s Apellis Pharmaceuticals position peaked at $13.7M in Q2 2023.
273 funds tracked by Wall St. Rank held Apellis Pharmaceuticals as of Q3 2025.

Based on Connor, Clark & Lunn Investment Management (CC&L)'s 13F filing for Q3 2025, filed 13 Nov 2025.